Hospira Drug Shortage Suit Must Be Revived, 11th Circuit Told

A putative class of individuals affected by Hospira’s decision to stop producing an injectable vitamin supplement on Thursday urged the 11th Circuit to revive their suit, alleging other companies may stop producing life-saving drugs if they don’t face the threat of similar litigation.
Law360